Skip to main content
Premium Trial:

Request an Annual Quote

NanoString, MD Anderson to Collaborate on Combination Gene, Protein Assays

NEW YORK (GenomeWeb) – NanoString Technologies today announced that it has formed a multi-year collaboration with the University of Texas MD Anderson Cancer Center to develop and test cancer biomarker assays that simultaneously profile gene and protein expression using the company's nCounter Analysis System.

Under the arrangement, the partners will develop new assays and signatures that profile key oncology disease pathways and immune response from tumor tissue. The assays will be incorporated into certain clinical studies being run at MD Anderson to predict and monitor responses to cancer immunotherapies and targeted therapies, and to identify clinically actionable proteomic markers across multiple tumor types.

NanoString said it holds the rights to research and diagnostic content generated through the collaboration.

"Our current PanCancer Pathway and Immune Profiling gene expression panels offer researchers … assays for understanding the tug-of-war between the drivers of tumor growth and the immune system's response," NanoString President and CEO Brad Gray said in a statement. "In collaboration with experts at MD Anderson, we will be adding a new proteomic dimension to these assays, and aiming to demonstrate their potential to inform drug development and selection."

NanoString said it plans to beta launch the first research panel for the simultaneous measurement of gene and protein expression at the American Association for Cancer Research annual meeting later this month.

The Scan

Tara Pacific Expedition Project Team Finds High Diversity Within Coral Reef Microbiome

In papers appearing in Nature Communications and elsewhere, the team reports on findings from the two-year excursion examining coral reefs.

Study Examines Relationship Between Cellular Metabolism, DNA Damage Repair

A new study in Molecular Systems Biology finds that an antioxidant enzyme shifts from mitochondria to the nucleus as part of the DNA damage response.

Stem Cell Systems Target Metastatic Melanoma in Mouse Model

Researchers in Science Translational Medicine describe a pair of stem cell systems aimed at boosting immune responses against metastatic melanoma in the brain.

Open Pediatric Brain Tumor Atlas Team Introduces Genomic Data Collection, Analytical Tools

A study in Cell Genomics outlines open-source methods being used to analyze and translate whole-genome, exome, and RNA sequence data from the Pediatric Brain Tumor Atlas.